US EditionNew Oral Antiretroviral Shows Potential as Long-Acting HIV Pre-Exposure Prophylaxis
MK-8527, a novel nucleoside reverse transcriptase translocation inhibitor, offers a promising once-monthly oral HIV prevention method, potentially improving adherence and privacy.
3 Articles
3 Articles
New oral antiretroviral shows potential as long-acting HIV pre-exposure prophylaxis
A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, USA, published August 26th in the open-access journal PLOS Biology.
Monthly pill shows potential as pre-exposure prophylaxis HIV drug candidate
A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, U.S., published in the open-access journal PLOS Biology.
New Monthly Oral PrEP Option for HIV Prevention Identified in Study by Merck Researchers
A recent study has identified a new antiretroviral drug […] The post New Monthly Oral PrEP Option for HIV Prevention Identified in Study by Merck Researchers first appeared on GeneOnline News. The post New Monthly Oral PrEP Option for HIV Prevention Identified in Study by Merck Researchers appeared first on GeneOnline News.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
